You have 9 free searches left this month | to do more

pembrolizumab

Pembrolizumab is a drug used to treat Melanoma, Non-small Cell Lung Cancer, Breast Cancer, and other conditions. Pembrolizumab is being actively studied in 808 studies and prior, has been studied in 111.

Top SponsorsTop SitesTop Investigators
Merck Sharp & Dohme Corp.Memorial Sloan Kettering Cancer CenterSara Tolaney
M.D. Anderson Cancer CenterDana Farber Cancer InstituteCCTU
National Cancer Institute (NCI)Massachusetts General HospitalDavid Reardon, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
  • Stage IIIA Non-Small Cell Lung Cancer
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
2021-07-06
Jul 6, 2021
N
Not yet recruiting
  • Metastatic Head and Neck Cancer
  • Recurrent Head and Neck Cancer
  • (no location specified)
2021-09-28
Sep 28, 2021
M
Not yet recruiting
  • Lung Cancer, Nonsmall Cell
  • Pembrolizumab
  • +3 more
  • (no location specified)
2021-05-07
May 7, 2021
A
Not yet recruiting
  • Non Hodgkin Lymphoma
  • Pembrolizumab
  • (no location specified)
2021-09-14
Sep 14, 2021
A
Not yet recruiting
  • Melanoma
  • (no location specified)
2021-07-12
Jul 12, 2021
P
Recruiting
  • Breast Cancer
  • Pembrolizumab
  • High-intensity focused ultrasound (HIFU)
  • Charlottesville, Virginia
    University of Virginia
2021-08-11
Aug 11, 2021
A
Active, not recruiting
  • Malignant Melanoma
  • pembrolizumab
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
2021-09-24
Sep 24, 2021
T
Terminated
  • Metastatic Colorectal Cancer
  • Kashiwa, Chiba, Japan
    National Cancer Center Hospital East
2021-08-30
Aug 30, 2021
M
Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
2021-09-07
Sep 7, 2021
J
Recruiting
  • Pancreatic Cancer
  • Lexington, Kentucky
    University of Kentucky Markey Cancer Center
2021-10-07
Oct 7, 2021
I
Not yet recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Pembrolizumab
  • Involved Field Radiation Therapy
  • Shanghai, China
    Shanghai Rui-Jin Hospital
2021-08-27
Aug 27, 2021
U
Recruiting
  • Pleural Mesothelioma
  • Pembrolizumab
  • Cisplatin and Pemetrexed
  • Chicago, Illinois
    University of Chicago
2021-06-29
Jun 29, 2021
E
Active, not recruiting
  • Transitional Cell Carcinoma of the Bladder
  • Biomarkers
  • Pembrolizumab
  • Rotterdam, Netherlands
    Erasmus MC
2021-08-19
Aug 19, 2021
P
Suspended
  • Metastatic Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Portland, Oregon
    Portland Providence Medical Center
2021-09-23
Sep 23, 2021
G
Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Pembrolizumab
  • (no location specified)
2021-03-29
Mar 29, 2021
C
Recruiting
  • NPC
  • Pembrolizumab
  • Hong Kong, Hong Kong
  • +1 more
2021-07-26
Jul 26, 2021
Y
Recruiting
  • Advanced Metastatic Melanoma
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
2021-09-13
Sep 13, 2021
S
Terminated
  • Patients With Leptomeningeal Disease
  • Pembrolizumab
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
2021-01-06
Jan 6, 2021
C
Recruiting
  • Acral Lentiginous Melanoma
  • pembrolizumab
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital
2021-07-26
Jul 26, 2021
D
Suspended
  • Glioblastoma
  • Boston, Massachusetts
  • +1 more
2021-08-13
Aug 13, 2021
U
Recruiting
  • Rectum Cancer
  • Rectal Cancer
  • Pembrolizumab
  • Geneva, Switzerland
    Hôpitaux Universitaires de Genève
2021-09-29
Sep 29, 2021
M
Completed
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • pembrolizumab
  • +3 more
  • (no location specified)
2021-07-29
Jul 29, 2021